Journal
BLOOD
Volume 119, Issue 26, Pages 6379-6381Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-03-418673
Keywords
-
Categories
Funding
- National Cancer Institute, National Institutes of Health [PO1 CA 30206, P30 CA33572, P50 CA107399, P01 CA044991]
- Tim Nesvig Lymphoma Research Fund
- K12 Paul Calabresi Career Development Award
- Tim Nesvig Lymphoma Fellowship
- Seattle Genetics
Ask authors/readers for more resources
Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed/refractory Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known. We retrospectively examined the records of 18 patients with relapsed/refractory Hodgkin lymphoma who were treated on brentuximab vedotin clinical trials to evaluate the efficacy and safety of subsequent reduced-intensity allo-HCT. Seventeen patients had previous autologous transplant; 6 were in complete remission, and 8 were in partial remission before allo-HCT with 12 grafts from unrelated or mismatched donors. The 1-year overall survival was 100%, progression-free survival was 92.3%, and nonrelapse mortality was 0% (median follow-up, 14 months). The incidence of acute GVHD was 27.8% and chronic GVHD was 56.3%. Brentuximab vedotin before reduced-intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo-HCT. (Blood. 2012;119(26):6379-6381)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available